Zobrazeno 1 - 10 of 408 pro vyhledávání: '"A. H. Goldstone"'
2
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
Autor: David I Marks, Amy A Kirkwood, Clare J Rowntree, Melanie Aguiar, Katharine E Bailey, Brendan Beaton, Paul Cahalin, Anna Z Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K McMillan, Mary Frances McMullin, Tobias F Menne, Rachel J Mitchell, Anthony V Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K Fielding
Publikováno v: Marks, D I, Kirkwood, A A, Rowntree, C J, Aguiar, M, Bailey, K E, Beaton, B, Cahalin, P, Castleton, A Z, Clifton-Hadley, L, Copland, M, Goldstone, A H, Kelly, R, Lawrie, E, Lee, S, McMillan, A K, McMullin, M F, Menne, T F, Mitchell, R J, Moorman, A V, Patel, B, Patrick, P, Smith, P, Taussig, D, Yallop, D, Alapi, K Z & Fielding, A K 2022, ' Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial ', The Lancet Haematology, vol. 9, no. 4, pp. e262-e275 . https://doi.org/10.1016/S2352-3026(22)00038-2
BACKGROUND: Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, ritux
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeb76af476ccd2c9482ebad9b933c975
https://doi.org/10.1016/s2352-3026(22)00038-2
Zobrazit plný text záznamu
4
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial
Autor: Ruth Pettengell, Ariane Boumendil, Joanna Romejko-Jarosinska, R Johnson, Peter Dreger, Stephen P. Robinson, Alejandro Martín, Eva Kimby, N. Schmitz, P Giri, Carsten Utoft Niemann, Anthony H. Goldstone, Isabelle Bence-Bruckler, Bernd Metzner, Silvia Montoto, Ruzena Uddin
Publikováno v: Bone Marrow Transplantation. 56:1413-1421
We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with relapsed follicular lymphoma (FL) receivin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1c505b8f93f04f2831c98fa7b98d651
https://doi.org/10.1038/s41409-020-01182-w
Zobrazit plný text záznamu
5
Akademický článek
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Autor: Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock
Publikováno v: Haematologica, Vol 101, Iss 11 (2016)
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have th
Externí odkaz: https://doaj.org/article/f772d011430040108f48560b445e89d7
Zobrazit plný text záznamu
7
Akademický článek
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
Autor: David I. Marks, Anthony V. Moorman, Lucy Chilton, Elisabeth Paietta, Amir Enshaie, Gordon DeWald, Christine J. Harrison, Adele K. Fielding, Letizia Foroni, Anthony H. Goldstone, Mark R. Litzow, Selina M. Luger, Andrew K. McMillan, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Peter Wiernik, Hillard M. Lazarus
Publikováno v: Haematologica, Vol 98, Iss 6 (2013)
The biology and outcome of adult t(4;11)(q21;q23)/MLL-AFF1 acute lymphoblastic leukemia are poorly understood. We describe the outcome and delineate prognostic factors and optimal post-remission therapy in 85 consecutive patients (median age 38 years
Externí odkaz: https://doaj.org/article/e001fb0cab064bd3a4369c1e67f8e80a
Zobrazit plný text záznamu
8
Akademický článek
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
Autor: Bella Patel, Keiren E. Kirkland, Richard Szydlo, Rachel M. Pearce, Richard E. Clark, Charles Craddock, Effie Liakopoulou, Adele K. Fielding, Stephen Mackinnon, Eduardo Olavarria, Mike N. Potter, Nigel H. Russell, Bronwen E. Shaw, Gordon Cook, Anthony H. Goldstone, David I. Marks
Publikováno v: Haematologica, Vol 94, Iss 10 (2009)
Background Approximately 40% of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia achieve long-term survival following unrelated donor hematopoietic stem cell transplantation in first complete remission but severe graft-versus
Externí odkaz: https://doaj.org/article/93328acd56e145d09c6d8acdb3eb9c6c
Zobrazit plný text záznamu
9
Response: Chemotherapy or allografting for young adults with high-risk ALL?
Autor: Susan M. Richards, Anthony H. Goldstone, Adele K. Fielding, Jacob M. Rowe
Publikováno v: Blood. 111(12)
We thank the correspondent and agree that the issue is important. We enclose [Table 1][1] of survival at 5 years in the subgroups requested by the correspondent, where standard risk (SR) and high risk (HR) refer to white cell count and lineage only.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::955b0636c4cd73a5e9eeff2e68521af5
https://pubmed.ncbi.nlm.nih.gov/31653127
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje